ERBB2 and neoplasm: The results showed targeted tumor cells with 1D5-PS and 1D5-18A12-PS induced significant tumor regression in trastuzumab-resistant high-HER2-expressing tumors, whereas in low-HER2-expressing tumors only a slight growth delay was observed.